Eight weeks treatment with sofosbuvir/ledipasvir in a 4-yearold child with chronic hepatitis C virus genotype 1 infection

Pediatric Infectious Disease Journal

Volumn 35, Issue 12, 2016, Pages 1373-

  Einsiedel, Hagen Graf ^a   Christiansen, Holger ^a   Wiegand, Johannes ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ANALOGS AND DERIVATIVES; CASE REPORT; CHRONIC HEPATITIS C; DRUG EFFECT; GENOTYPE; HEPACIVIRUS; HUMAN; MALE; PRESCHOOL CHILD;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHILD, PRESCHOOL; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; URIDINE MONOPHOSPHATE;

EID: 84995814192     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001336     Document Type: Letter

References (2)

1. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62:25-30.
2. Kowdley KV, Gordon SC, Reddy KR, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.